CN
CN

CN
Gene therapy

General Adeno-associated Viral Vector (AAV) Platforms

 

  • Customized recombinant AAV (rAAV) genome construction and validation
  • General AAV packaging, purification and tittering
  • Premade AAV control vectors
  • In vitro and in vivo transduction

Fig 1. Customized recombinant AAV (rAAV) genome construction

 

Fig 2. In vitro validation by two clinically-relevant rAAV vectors

 

 

AAV-mediated Gene Replacement Therapy

 

    • Customized therapeutic rAAV vector design, construction and packaging
    • In vitro validation of the therapeutic effect
    • Dose-escalation long-term efficacy and safety evaluation in vivo including wild type and disease models

 

Fig 3. Schematic diagram of AAV-mediated Gene Replacement Therapy

 

Fig4. Efficacy and safety evaluation of AAV8-Gene A in vivo.
a. Biodistribution of AAV8-GFP in mice.
b. Transduction efficiency of AAV8-GFP vector in liver.
c. Gene A expression levels in mice at week 1, 2, 4, 6 and 8 post viral delivery.
d. No alanine transaminase (ALT) change demonstrate the safety of the gene delivery.  

 

 

AAV-mediated In Vivo Genome Editing and Therapy

 

  • Customized rAAV vector design , construction and packaging for in vivo genome editing
  • In vitro validation of genome editing
  • In vivo genome editing efficiency and functional evaluation

 

Fig 5. Schematic diagram of in vivo genome editing and therapy

 

Fig 6. Validation of in vivo KO by AAV8-sgGene B. a, Editing efficiency of AAV8-sgGene B. b, Representative indels formation in liver tissue.

 

 

Business Contact: